1 |
Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 2007; 179: 3161-3170. https://doi.org/10.4049/jimmunol.179.5.3161
DOI
|
2 |
Carrion J, Folgueira C, Soto M, Fresno M, Requena JM. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit Vectors 2011; 4: 150. https://doi.org/10.1186/1756-3305-4-150
DOI
|
3 |
Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001; 19: 3169-3178. https://doi.org/10.1016/S0264-410X(01)00023-8
DOI
|
4 |
Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, Nakhasi HL. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit longterm protective immunity in BALB/c mice. J Immunol 2013; 190: 2138-2149. https://doi.org/10.4049/jimmunol.1202801
DOI
|
5 |
Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9: 1899-1907. https://doi.org/10.1089/hum.1998.9.13-1899
DOI
|
6 |
Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of Leishmania vaccines: predicting the future from past and present experience. J Biomed Res. 2013; 27: 85-102. https://doi.org/10.7555/JBR.27.20120064
DOI
|
7 |
Aunguldee T, Gerdprasert O, Tangteerawatana P, Jariyapongskul A, Leelayoova S, Wongsatayanon BT. Immunogenicity and potential protection of DNA vaccine of Leishmania martiniquensis against Leishmania infection in mice. J Infect Dev Ctries 2021; 15: 1328-1338. https://doi.org/10.3855/jidc.14472
DOI
|
8 |
Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol 2008; 118: 393-401. https://doi.org/10.1016/j.exppara.2007.10.004
DOI
|
9 |
Prasanna P, Kumar P, Kumar S, Rajana VK, Kant V, Prasad SR, Mohan U, Ravichandiran V, Mandal D. Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis-a review. Biomed Pharmacother 2021; 141: 111920. https://doi.org/10.1016/j.biopha.2021.111920
DOI
|
10 |
Kaye P, University of York. A study to assess the safety, efficacy and immunogenicity of Leishmania vaccine ChAd63-KH in PKDL [Internet]; [cited 2022 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03969134
|
11 |
Taheri T, Rafati S. Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development. Clin Invest 2013; 3: 1023-1044. https://doi.org/10.4155/CLI.13.99
DOI
|
12 |
Volpedo G, Huston RH, Holcomb EA, Pacheco-Fernandez T, Gannavaram S, Bhattacharya P, Nakhasi HL, Satoskar AR. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert Rev Vaccines 2021; 20: 1431-1446. https://doi.org/10.1080/14760584.2021.1969231
DOI
|
13 |
Cecilio P, Perez-Cabezas B, Fernandez L, Moreno J, Carrillo E, Requena JM, Fichera E, Reed SG, Coler RN, Kamhawi S, Oliveira F, Valenzuela JG, Gradoni L, Glueck R, Gupta G, Cordeiroda-Silva A. Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Negl Trop Dis 2017; 11: e0005951. https://doi.org/10.1371/journal.pntd.0005951
DOI
|
14 |
Taslimi Y, Zahedifard F, Taheri T, Doroud D, Dizaji SL, Saljoughian N, Rafati S. Comparison of protective potency of DNA and live vaccines expressing A2-CPA-CPB-CTE antigens against visceral leishmaniasis in Syrian hamster as preliminary study. Iran J Parasitol 2020; 15: 383-392. https://doi.org/10.18502/ijpa.v15i3.4203
DOI
|
15 |
Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, Wiggins R, Di Marco S, Colloca S, Siani L, Cortese R, Smith DF, Aebischer T, Kaye PM, Lacey CJ. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 2017; 11: e0005527. https://doi.org/10.1371/journal.pntd.0005527
DOI
|
16 |
Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol 2018; 9: 2224. https://doi.org/10.3389/fimmu.2018.02224
DOI
|
17 |
Margaroni M, Agallou M, Athanasiou E, Kammona O, Kiparissides C, Gaitanaki C, Karagouni E. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. Int J Nanomedicine 2017; 12: 6169-6184. https://doi.org/10.2147/IJN.S141069
DOI
|
18 |
Lage DP, Ribeiro PA, Dias DS, Mendonca DV, Ramos FF, Carvalho LM, de Oliveira D, Steiner BT, Martins VT, Perin L, Machado AS, Santos TTO, Tavares GSV, Oliveira-da-Silva JA, Oliveira JS, Roatt BM, Machado-de-Avila RA, Teixeira AL, Humbert MV, Coelho EAF, Christodoulides M. A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitopecontaining chimeric protein protects mice Against Leishmania infantum infection. NPJ Vaccines 2020; 5: 75. https://doi.org/10.1038/s41541-020-00224-0
DOI
|
19 |
Klatt S, Simpson L, Maslov DA, Konthur Z. Leishmania tarentolae: taxonomic classification and its application as a promising biotechnological expression host. PLoS Negl Trop Dis 2019; 13: e0007424. https://doi.org/10.1371/journal.pntd.0007424
DOI
|
20 |
Alves-Silva MV, Nico D, de Luca PM, Palatnik de-Sousa CB. The F1F3 recombinant chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and its epitopes induce cross-protection against Leishmania (V.) braziliensis infection in mice. Front Immunol 2019; 10: 724. https://doi.org/10.3389/fimmu.2019.00724
DOI
|
21 |
Mendoza-Roldan JA, Latrofa MS, Iatta R, RS Manoj R, Panarese R, Annoscia G, Pombi M, Zatelli A, Beugnet F, Otranto D. Detection of Leishmania tarentolae in lizards, sand flies and dogs in southern Italy, where Leishmania infantum is endemic: hindrances and opportunities. Parasit Vectors 2021; 14: 461. https://doi.org/10.1186/s13071-021-04973-2
DOI
|
22 |
Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005; 73: 6372-6382. https://doi.org/10.1128/IAI.73.10.6372-6382.2005
DOI
|
23 |
Panasiuk M, Zimmer K, Czarnota A, Grzyb K, Narajczyk M, Peszynska-Sularz G, Zoledowska S, Nidzworski D, Hovhannisyan L, Gromadzka B. Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies. Microbial Cell Factories 2021; 20: 186. https://doi.org/10.1186/s12934-021-01677-1
DOI
|
24 |
Moura AP, Santos LC, Brito CR, Valencia E, Junqueira C, Filho AA, Sant'Anna MR, Gontijo NF, Bartholomeu DC, Fujiwara RT, Gazzinelli RT, McKay CS, Sanhueza CA, Finn MG, Marques AF. Virus-like particle display of the α-Gal carbohydrate for vaccination against Leishmania infection. ACS central science 2017; 3: 1026-1031. https://doi.org/10.1021/acscentsci.7b00311
DOI
|
25 |
Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu FC, Stinchcomb DT, Reed SG. Heterologous immunization with defined RNA and subunit vaccines enhances T Cell responses that protect against Leishmania donovani. Front Immunol 2018; 9: 2420. https://doi.org/10.3389/fimmu.2018.02420
DOI
|
26 |
Dinc R. New developments in the treatment of cutaneous leishmaniasis. Asian Pac J Trop Med 2022; 15: 196-205. https://doi.org/10.4103/1995-7645.345944
DOI
|
27 |
Yesilova Y, Aksoy M, Surucu HA, Uluat A, Ardic N, Yesilova A. Lip leishmaniasis: Clinical characteristics of 621 patients. Int J Crit Illn Inj Sci. 2015; 5: 265-266. https://doi.org/10.4103/2229-5151.170849
DOI
|
28 |
Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob Health 2021; 9: e1763-1769. https://doi.org/10.1016/S2214-109X(21)00392-2
DOI
|
29 |
De Beuckelaer A, Grooten J, De Koker S. Type I interferons modulate CD8+ T cell immunity to mRNA vaccines. Trends Mol Med 2017; 23: 216-226. https://doi.org/10.1016/j.molmed.2017.01.006
DOI
|
30 |
Versteeg L, Almutairi MM, Hotez PJ, Pollet J. Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines 2019; 7: 122. https://doi.org/10.3390/vaccines7040122
DOI
|
31 |
Duthie MS, Machado BA, Badaro R, Kaye PM, Reed SG. Leishmaniasis vaccines: applications of RNA technology and targeted clinical trial designs. Pathogens 2022; 11: 1259. https://doi.org/10.3390/pathogens11111259
DOI
|
32 |
Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors 2016; 9: 277. https://doi.org/10.1186/s13071-016-1553-y
DOI
|
33 |
Bezemer JM, Meesters K, Naveda CL, Machado PRL, Calvopina M, Leeflang MMG, Schallig HDFH, de Vries HJC. Clinical criteria for Mucosal leishmaniasis diagnosis in rural South America: a systematic literature review. PLoS Negl Trop Dis 2022 16: e0010621. https://doi.org/10.1371/journal.pntd.0010621
DOI
|
34 |
Martins-Melo FR, Lima Mda S, Ramos AN Jr, Alencar CH, Heukelbach J. Mortality and case fatality due to visceral leishmaniasis in Brazil: a nationwide analysis of epidemiology, trends and spatial patterns. PLoS One. 2014; 9: e93770. https://doi.org/10.1371/journal.pone.0093770
DOI
|
35 |
World Health Organization. Leishmaniasis: Situation and trend [Internet]; [cited 2022 Aug 29]. Available from: https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/leishmaniasis#:~:text=As%20of%20September%202021%2C%2055,Somalia%2C%20South%20Sudan%20and%20Sudan
|
36 |
Malvolti S, Malhame M, Mantel CF, Le Rutte EA, Kaye PM. Human leishmaniasis vaccines: Use cases, target population and potential global demand. PLoS Negl Trop Dis 2021; 15: e0009742. https://doi.org/10.1371/journal.pntd.0009742
DOI
|
37 |
Jha MK, Sarode AY, Bodhale N, Mukherjee D, Pandey SP, Srivastava N, Rub A, Silvestre R, Sarkar A, Saha B. Development and characterization of an avirulent Leishmania major strain. J Immunol 2020; 204: 2734-2753. https://doi.org/10.4049/jimmunol.1901362
DOI
|
38 |
Silva CFM, Pinto DCGA, Fernandes PA, Silva AMS. Evolution of acridines and xanthenes as a core structure for the development of antileishmanial agents. Pharmaceuticals (Basel) 2022; 15: 148. https://doi.org/10.3390/ph15020148
DOI
|
39 |
Ardic N, Ardic AF, Gunel Z. Leishmaniasis during the increased Syrian refugee traffic. Glob J Infect Dis Clin Res 2018; 4: 013-016. http://dx.doi.org/10.17352/2455-5363.000020
DOI
|
40 |
Santana W, de Oliveira SS, Ramos MH, Santos ALS, Dolabella SS, Souto EB, Severino P, Jain S. Exploring innovative leishmaniasis treatment: drug targets from pre-clinical to clinical findings. Chem Biodivers 2021; 18: e2100336. https://doi.org/10.1002/cbdv.202100336
DOI
|
41 |
de Morais RC, de Melo MG, de Goes TC, e Silva RP, de Morais RF, de Oliveira Guerra JA, de Brito ME, Brandao-Filho SP, de Paiva Cavalcanti M. Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil. Exp Parasitol 2022; 240: 108338. https://doi.org/10.1016/j.exppara.2022.108338
DOI
|
42 |
World Health Organization. Leishmaniasis[Internet]; [cited 2022 Aug 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
|
43 |
Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pecoul B, Rijal S, Rode J, Solomos A. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev 2018; 31: e00048-18. https://doi.org/10.1128/CMR.00048-18
DOI
|
44 |
Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, Siddiqui A, Simonyan V, Oliveira F, Coutinho-Abreu IV, DeSouza-Vieira T, Meneses C, Oristian J, Serafim TD, Musa A, Nakamura R, Saljoughian N, Volpedo G, Satoskar M, Satoskar S, Dagur PK, McCoy JP, Kamhawi S, Valenzuela JG, Hamano S, Satoskar AR, Matlashewski G, Nakhasi HL. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat Commun 2020; 11: 3461. https://doi.org/10.1038/s41467-020-17154-z
DOI
|
45 |
Karmakar S, Ismail N, Oliveira F, Oristian J, Zhang WW, Kaviraj S, Singh KP, Mondal A, Das S, Pandey K, Bhattacharya P, Volpedo G, Gannavaram S, Satoskar M, Satoskar S, Sastry RM, Oljuskin T, Sepahpour T, Meneses C, Hamano S, Das P, Matlashewski G, Singh S, Kamhawi S, Dey R, Valenzuela JG, Satoskar A, Nakhasi HL. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun Biol 2021; 4: 929. https://doi.org/10.1038/s42003-021-02446-x
DOI
|
46 |
Miramin-Mohammadi A, Javadi A, Eskandari SE, Nateghi-Rostami M, Khamesipour A. Immune responses in cutaneous leishmaniasis: In vitro Thelper1/Thelper2 cytokine profiles using live versus killed Leishmania major. J Arthropod Borne Dis 2021; 15: 126-135. https://doi.org/10.18502/jad.v15i1.6491
DOI
|
47 |
Carregaro V, Costa DL, Brodskyn C, Barral AM, Barral-Netto M, Cunha FQ, Silva JS. Dual effect of Lutzomyia longipalpis saliva on Leishmania braziliensis infection is mediated by distinct saliva-induced cellular recruitment into BALB/c mice ear. BMC Microbiol 2013; 13: 102. https://doi.org/10.1186/1471-2180-13-102
DOI
|
48 |
Helou DG, Mauras A, Fasquelle F, Lanza JS, Loiseau PM, Betbeder D, Cojean S. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. PLoS Negl Trop Dis. 2021; 15: e0009627. https://doi.org/10.1371/journal.pntd.0009627
DOI
|
49 |
Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. Front Immunol 2014; 5: 134. https://doi.org/10.3389/fimmu.2014.00134
DOI
|
50 |
Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003; 131: 457-467. https://doi.org/10.1046/j.1365-2249.2003.02096.x
DOI
|
51 |
Ikeogu NM, Akaluka GN, Edechi CA, Salako ES, Onyilagha C, Barazandeh AF, Uzonna JE. Leishmania immunity: advancing immunotherapy and vaccine development. Microorganisms 2020; 8: 1201. https://doi.org/10.3390/microorganisms8081201
DOI
|
52 |
Kopelyanskiy D, Desponds C, Prevel F, Rossi M, Migliorini R, Snaka T, Eren RO, Claudinot S, Lye LF, Pasparakis M, Beverley SM, Fasel N. Leishmania guyanensis suppressed inducible nitric oxide synthase provoked by its viral endosymbiont. Front Cell Infect Microbiol 2022; 12: 944819. https://doi.org/10.3389/fcimb.2022.944819
DOI
|
53 |
Cecilio P, Cordeiro-da-Silva A, Oliveira F. Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites. Commun Biol 2022; 5: 305. https://doi.org/10.1038/s42003-022-03240-z
DOI
|
54 |
Cummings HE, Tuladhar R, Satoskar AR. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J Biomed Biotechnol 2010; 2010: 294389. https://doi.org/10.1155/2010/294389
DOI
|
55 |
Natarajan G, Oghumu S, Varikuti S, Thomas A, Satoskar A. Mechanisms of immunopathology of leishmaniasis. In Satoskar AR, Durvasula R eds, Pathogenesis of Leishmaniasis. Springer. New York, USA. 2014, pp 1-13.
|
56 |
Volpedo G, Pacheco-Fernandez T, Bhattacharya P, Oljuskin T, Dey R, Gannavaram S, Satoskar AR, Nakhasi HL. Determinants of innate immunity in visceral leishmaniasis and their implication in vaccine development. Front Immunol 2021; 12: 748325. https://doi.org/10.3389/fimmu.2021.748325
DOI
|
57 |
Abdellahi L, Iraji F, Mahmoudabadi A, Hejazi SH. Vaccination in leishmaniasis: a review article. Iran Biomed J 2022; 26: 1-35. https://doi.org/10.52547/ibj.26.1.35
DOI
|
58 |
Sumova P, Sanjoba C, Willen L, Polanska N, Matsumoto Y, Noiri E, Paul SK, Ozbel Y, Volf P. PpSP32-like protein as a marker of human exposure to Phlebotomus argentipes in Leishmania donovani foci in Bangladesh. Int J Parasitol 2021; 51: 1059-1068. https://doi.org/10.1016/j.ijpara.2021.05.006
DOI
|
59 |
Hosseini Farash BR, Mohebali M, Kazemi B, Fata A, Hajjaran H, Akhoundi B, Raoofian R, Mastroeni P, Moghaddas E, Khaledi A, Salehi Sangani G. Validation of a mixture of rK26 and rK39 antigens from Iranian strain of Leishmania infantum to detect anti-Leishmania antibodies in human and reservoir hosts. Sci Rep 2022; 12: 10426. https://doi.org/10.1038/s41598-022-14490-6
DOI
|
60 |
Gomes DC, Souza BL, Schwedersky RP, Covre LP, de Matos Guedes HL, Lopes UG, Re MI, Rossi-Bergmann B. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis. Microbes Infect 2022; 24: 104884. https://doi.org/10.1016/j.micinf.2021.104884
DOI
|
61 |
Goyal DK, Keshav P, Kaur S. Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice. Microb Pathog 2021; 158: 105021. https://doi.org/10.1016/j.micpath.2021.105021
DOI
|
62 |
Bhaumik SK, Singh MK, Karmakar S, De T. UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj J 2009; 26: 663-673. https://doi.org/10.1007/s10719-008-9212-y
DOI
|
63 |
De Luca PM, Macedo AB. Cutaneous leishmaniasis vaccination: a matter of quality. Front Immunol 2016; 7: 151. https://doi.org/10.3389/fimmu.2016.00151
DOI
|
64 |
Pacheco-Fernandez T, Volpedo G, Gannavaram S, Bhattacharya P, Dey R, Satoskar A, Matlashewski G, Nakhasi HL. Revival of leishmanization and leishmanin. Front Cell Infect Microbiol 2021; 11: 639801. https://doi.org/10.3389/fcimb.2021.639801
DOI
|
65 |
Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. Vaccine 2013; 31: B244-B249. https://doi.org/10.1016/j.vaccine.2012.11.080
DOI
|
66 |
Ostolin TL, Gusmao MR, Mathias FA, de Oliveira Cardoso JM, Roatt BM, de Oliveira Aguiar-Soares RD, Ruiz JC, de Melo Resende D, de Brito RC, Reis AB. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Vaccine 2021; 39: 2755-2763. https://doi.org/10.1016/j.vaccine.2021.04.004
DOI
|
67 |
Athanasiou E, Agallou M, Tastsoglou S, Kammona O, Hatzigeorgiou A, Kiparissides C, Karagouni E. A poly (lactic-co-glycolic) acid nanovaccine based on chimeric peptides from different Leishmania infantum proteins induces dendritic cells maturation and promotes peptide-specific IFNγ-producing CD8+ T cells essential for the protection against experimental visceral leishmaniasis. Front Immunol 2017; 8: 684. https://doi.org/10.3389/fimmu.2017.00684
DOI
|
68 |
Mohebali M, Nadim A, Khamesipour A. An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. Acta Trop 2019; 200: 105173. https://doi.org/10.1016/j.actatropica.2019.105173
DOI
|
69 |
Oliveira F, Rowton E, Aslan H, Gomes R, Castrovinci PA, Alvarenga PH, Abdeladhim M, Teixeira C, Meneses C, Kleeman LT, Guimaraes-Costa AB, Rowland TE, Gilmore D, Doumbia S, Reed SG, Lawyer PG, Andersen JF, Kamhawi S, Valenzuela JG. A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates. Sci Transl Med 2015; 7: 290ra90. https://doi.org/10.1126/scitranslmed.aaa3043
DOI
|
70 |
Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, Torkashvand F, Meneses C, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Enhanced protective efficacy of nonpathogenic recombinant Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS Negl Trop Dis 2014; 8: e2751. https://doi.org/10.1371/journal.pntd.0009123
DOI
|
71 |
Davarpanah E, Seyed N, Bahrami F, Rafati S, Safaralizadeh R, Taheri T. Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice. PLoS Negl Trop Dis 2020; 14: e0007939. https://doi.org/10.1371/journal.pntd.0007939
DOI
|
72 |
Mitchell GF, Handman E, Spithill TW. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984; 62: 145-153. https://doi.org/10.1038/icb.1984.14
DOI
|
73 |
Gorczynski RM. Immunization of susceptible BALB/c mice against Leishmania braziliensis,: II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cellular Immunol 1985; 94: 11-20. https://doi.org/10.1016/0008-8749(85)90081-4
DOI
|
74 |
Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 1993; 15: 75-84. https://doi.org/10.1111/j.1365-3024.1993.tb00587.x
DOI
|
75 |
Kimsey PB, Theodos CM, Mitchen TK, Turco SJ, Titus RG. An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect Immun 1993; 61: 5205-5213. https://doi.org/10.1128/iai.61.12.5205-5213.1993
DOI
|
76 |
Moafi M, Rezvan H, Sherkat R, Taleban R. Leishmania vaccines entered in clinical trials: A review of literature. Int J Prev Med 2019; 10: 95. https://doi.org/10.4103/ijpvm.IJPVM_116_18
DOI
|
77 |
Daneshvar H, Coombs GH, Hagan P, Phillips RS. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 2003; 187: 1662-1668. https://doi.org/10.1086/374783
DOI
|
78 |
Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, Mazzedo MI, Blanco B. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004; 99: 57-62. https://doi.org/10.1590/S0074-02762004000100010
DOI
|
79 |
Araujo MS, de Andrade RA, Vianna LR, Mayrink W, Reis AB, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Mello MN, Martins-Filho OA. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008; 26: 2211-2224. https://doi.org/10.1016/j.vaccine.2008.02.044
DOI
|
80 |
Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villarroel H, Zapata Z, Tomedes I. Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 2003; 97: 469-472. https://doi.org/10.1016/S0035-9203(03)90093-9
DOI
|
81 |
Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther 2014; 141641-9. https://doi.org/10.1517/14712598.2014.945415
DOI
|
82 |
Velez R, Gallego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Trop Med Int Health 2020; 25: 540-557. https://doi.org/10.1111/tmi.13382
DOI
|
83 |
Parody N, Soto M, Requena JM, Alonso C. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG+Q mix protects Balb/c mice from infection. Parasite Immunol 2004; 26: 283-293. https://doi.org/10.1111/j.0141-9838.2004.00711.x
DOI
|
84 |
Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, Soares IS, Batista LMM, Palatnik-de-Sousa CB. Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2008; 26: 4991-4997. https://doi.org/10.1016/j.vaccine.2008.07.029
DOI
|
85 |
The European Public Assessment. CaniLeish: canine vaccine against Leishmania infantum adjuvanted [Internet]; The European Public Assessment; [cited 2022 Aug 29]. Available from: https://www.ema.europa.eu/en/documents/overview/canileishepar-summary-public_en.pdf
|
86 |
Moreno J, Vouldoukis I, Martin V, McGahie D, Cuisinier AM, Gueguen S. Use of a LIESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs. PLoS Negl Trop Dis 2012: 6: e1683. https://doi.org/10.1371/journal.pntd.0001683
DOI
|
87 |
Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 2004; 22: 1631-1639. https://doi.org/10.1016/j.vaccine.2003.10.046
DOI
|
88 |
Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, Koech DK, McMaster WR. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Vet Parasitol 1995; 60: 199-212. https://doi.org/10.1016/0304-4017(95)00788-6
DOI
|
89 |
Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major Leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145: 2281-2285.
DOI
|
90 |
Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186: 1137-1147. https://doi.org/10.1084/jem.186.7.1137
DOI
|
91 |
McMahon-Pratt D, Rodriguez D, Rodriguez JR, Zhang Y, Manson K, Bergman C, Rivas L, Rodriguez JF, Lohman KL, Ruddle NH. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 1993; 61: 3351-3359. https://doi.org/10.1128/iai.61.8.3351-3359.1993
DOI
|
92 |
Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56: 3272-3279. https://doi.org/10.1128/iai.56.12.3272-3279.1988
DOI
|
93 |
Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63: 4261-4267. https://doi.org/10.1128/iai.63.11.4261-4267.1995
DOI
|
94 |
Santos WR, Aguiar IA, de Souza EP, de Lima VM, Palatnik M, Palatnik-de-Sousa CB. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 2003; 21: 4668-4676. https://doi.org/10.1016/S0264-410X(03)00527-9
DOI
|
95 |
Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 2011; 11: 1464-1488. https://doi.org/10.1016/j.intimp.2011.05.008
DOI
|
96 |
Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012; 30: 134-141. https://doi.org/10.1016/j.vaccine.2011.11.005
DOI
|
97 |
Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology 2015; 4: e35. https://doi.org/10.1038/cti.2015.6
DOI
|
98 |
Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine 2016; 34: 2992-2995. https://doi.org/10.1016/j.vaccine.2015.12.071
DOI
|
99 |
Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011; 29: 3531-3537. https://doi.org/10.1016/j.vaccine.2011.02.096
DOI
|
100 |
Gannavaram S, Dey R, Avishek K, Selvapandiyan A, Salotra P, Nakhasi HL. Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis-discovery and implications. Front Immunol 2014; 5: 241. https://doi.org/10.3389/fimmu.2014.00241
DOI
|
101 |
Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, Fillion I, Singh AK, Olivier M, Ouellette M. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 2002; 70: 62-68. https://doi.org/10.1128/IAI.70.1.62-68.2002
DOI
|